Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Trading Update

13 Feb 2018 07:00

RNS Number : 6519E
Itaconix PLC
13 February 2018
 

13 February 2018

Itaconix plc ("Itaconix") Year End Trading Update - Positioned for Growth

Itaconix, a leading innovator in sustainable performance polymers, today announces a trading update for the year ended 31 December 2017.

Itaconix is a leader in bio-based polymers based on itaconic acid. The Company uses an established proprietary process with break-through economics to produce unique or enhanced ingredients for the homecare, personal care and industrial markets.

Key provisional unaudited financial measures for the year ended 31 December 2017 were:

2017 (unaudited)

2016

Revenue

£0.6m

£0.3m

Group Operating Loss*

£5.2m

£5.2m

Cash

£3.6m

£8.8m

*: Group Operating Loss is stated before the non cash impairments disclosed below.

 

Key Developments

· Routes to market established through key partnerships signed with:

o Croda Inc

o AkzoNobel Performance Additives

o AkzoNobel Chelates

· Distributor network established for the Personal Care business

· First sales and repeat sales of:

o Itaconix® ZINADORTM for malodour management

o RevCareTM NE 100S hairstyling polymer

· Royalties from first sales of EurecoTM RP103, a product developed by Itaconix and licensed to Solvay SA, and an announcement that Società Chimica Bussi S.p.A. has decided to invest in facilities for the scaled production of this material

· While the new product adoptions and sales partnerships have positioned Itaconix well for the future, sales revenue growth in 2017 was slower than anticipated (as already notified to the market at the time of the interim results in September 2017)

· As a result of the slower than anticipated growth, the goodwill associated with the acquisition of Itaconix Corporation has been fully impaired by £6.1 million. In addition, the valuation of contingent consideration payable in shares to the original shareholders of Itaconix Corporation has been reduced from £3.4m at 31 December 2016 to £1.1m at 31 December 2017. The charges and credits, respectively, associated with these changes are non cash and will be recognised as exceptional items in the income statement for 2017 below the Group Operating Loss stated above**

· Completed $1m investment programme in polymer production capacity in New Hampshire

· In January 2018, concluded a licence and assignment agreement of non-core polymer assets to tremco-illbruck for use in construction sealants.

Dr Bryan Dobson, Chairman, said

"Itaconix has achieved real commercial progress in 2017, albeit at a slower than anticipated revenue growth rate. The business is now well positioned with products in market and channels in place, both through major strategic partnerships with parties such as Solvay, Croda and AkzoNobel as well as a distribution network for Personal Care. The Board is confident that the Company is now well positioned to deliver revenue growth from 2018."

**: Whilst the Board believes that the Company is well positioned to deliver significant revenue growth in the medium to longer term, it is anticipated that this will take longer to deliver than previously envisaged. Goodwill is calculated as the difference between the enterprise value and the fair value of the net assets at the time the business is acquired. Its value is subsequently estimated using discounted cash flow techniques based on medium term board approved forecasts, and consequently delays in revenue and earnings can have a material effect on the value of goodwill and intangibles. The value of the contingent consideration is also impacted by lower medium term board approved revenue forecasts, as the consideration depends on revenue achieved in the four years 2017 to 2020 inclusive.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).

 

Ends

For further information please contact:

Itaconix plc +44 (0) 1244 283 500

Kevin Matthews / Rob Cridland

N+1 Singer +44 (0) 207 496 3000

Richard Lindley / Liz Yong

Hudson Sandler

Charlie Jack / Emily Dillon +44 (0) 207 796 4133

About Itaconix

Itaconix is developing proprietary ingredients that meet the performance and price needs of its customers and offers them improved safety and sustainability, thereby helping to deliver on the global sustainability agenda, with particular emphasis on the Personal Care and Homecare markets.

 

www.Itaconix.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTBCGDDCXBBGID
Date   Source Headline
3rd May 20197:00 amRNSFirst European Order for New Detergent Polymer
2nd Apr 20194:41 pmRNSSecond Price Monitoring Extn
2nd Apr 20194:35 pmRNSPrice Monitoring Extension
28th Feb 20192:05 pmRNSSecond Price Monitoring Extn
28th Feb 20192:00 pmRNSPrice Monitoring Extension
28th Feb 20199:00 amRNSPersonal care agreement with Nouryon
18th Feb 201911:06 amRNSSecond Price Monitoring Extn
18th Feb 201911:00 amRNSPrice Monitoring Extension
18th Feb 20197:00 amRNSFull Year Trading Update
15th Jan 20194:40 pmRNSSecond Price Monitoring Extn
15th Jan 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20199:00 amRNSDetergent polymer agreement with Nouryon
9th Jan 20192:20 pmRNSBlock listing Interim Review
5th Dec 20187:00 amRNSNew Licence Agreement with New Wave
26th Oct 20187:00 amRNSDirectorate Change
2nd Oct 20187:00 amRNSBoard Changes
27th Sep 20187:00 amRNSInterim results
9th Aug 20181:41 pmRNSResult of AGM
6th Aug 20187:00 amRNSAppointment of Interim Chief Financial Officer
3rd Aug 20188:51 amRNSDirector/PDMR Dealings
3rd Aug 20188:47 amRNSBoard Changes
2nd Aug 201812:49 pmRNSExercise of Options, Directors' Dealing & TVR
2nd Aug 201811:57 amRNSResult of General Meeting
1st Aug 201810:02 amRNSResult of Open Offer & US Additional Subscription
16th Jul 20187:30 amRNSRestoration - Itaconix plc
13th Jul 20183:58 pmRNSReplacement re Further Details on the Fundraising
13th Jul 20183:54 pmRNSBlock listing Interim Review
13th Jul 20183:26 pmRNSRestoration of Trading
13th Jul 201812:11 pmRNSPosting of Circular & Annual Report & Notice of GM
12th Jul 20184:47 pmRNSFurther Details on the Fundraising
12th Jul 20187:05 amRNSProposed Fundraising
12th Jul 20187:00 amRNSPreliminary Results
29th Jun 20187:30 amRNSSuspension - Itaconix Plc
29th Jun 20187:30 amRNSSuspension of Share Trading and Financing Update
30th May 201810:00 amRNSOperational Update
16th May 20187:00 amRNSJoint marketing effort defined with AkzoNobel
16th Apr 20187:25 amRNSQ1 2018 Trading Update
13th Feb 20187:00 amRNSTrading Update
1st Feb 20187:00 amRNSBlock listing Interim Review
25th Jan 20187:00 amRNSLicence and assignment agreement with tremco
16th Oct 20179:00 amRNSSocietà Chimica Bussi investing in capacity
18th Sep 20177:00 amRNSInterim Results
5th Sep 20179:04 amRNSBio-based chelates for the detergents industry
26th Jul 20172:00 pmRNSFirst Bio-based Polymer Application Agreement
10th Jul 20177:00 amRNSBlock listing Interim Review
1st Jun 20171:19 pmRNSGrant of options
25th May 201712:42 pmRNSResult of AGM
18th May 20177:00 amRNSOperational Update
26th Apr 201711:01 amRNSHolding(s) in Company
18th Apr 20177:00 amRNSNotice of AGM and Posting of Annual Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.